A Study of TL-925 for the Treatment of Allergic Conjunctivitis

Summary

In this prospective Phase 2, single-center, randomized, double-masked, placebo-controlled study, approximately 70 subjects with allergic conjunctivitis will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.

Timeline

Start

2023-11

Primary completion

2024-01

Completion

2024-01

Drugs

Indications